Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp185 | Pituitary / Growth Hormone ' IGF Axis | ECE2018

Long-term treatment with metyrapone in four patients with Cushing’s disease

Driessens Natacha , Maiter Dominique , Borensztein Pascale , Jaspart Amelie , Bostnavaron Martine , Beckers Albert

Introduction: CushingÂ’s disease (CD) is a severe disease, associated with an increased rate of comorbidities and mortality. Remission rate after surgery of pituitary tumor, is around 78%. Relapse occurs in 13% of patients within 10-years after surgery. According to guidelines, patients with unfeasible or non-curative surgery, require additional treatment, including medical therapies. Metyrapone, inhibits 11ß-hydroxylase enzyme, blocking the final step of cortisol syn...

ea0056p859 | Pituitary - Clinical | ECE2018

PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing’s syndrome

Nieman Lynnette , Akinci Baris , Beckers Albert , Bolanowski Marek , Hanzu Felicia Alexandra , Mezosi Emese , Tonjes Anke , Bostnavaron Martine , Jaspart Amelie , Borensztein Pascale , Boscaro Marco , Scaroni Carla

Introduction: Metyrapone blocks cortisol production by inhibiting 11ß-hydroxylation of 11-deoxycortisol, the last step of cortisol synthesis. Based on observational retrospective studies published over more than 50 years metyrapone is approved for the treatment of endogenous CushingÂ’s syndrome (CS) in 14 European countries. PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern assay techniques.Desi...